There are currently 1555 clinical trials in Baltimore, Maryland looking for participants to engage in research studies. Trials are conducted at various facilities, including Johns Hopkins University, Johns Hopkins Hospital, University of Maryland and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)
NCT01169194
Recruiting
The investigators are doing the research to discover genes that cause Inflammatory Bowel Disease (IBD) specifically in the African American population. African Americans with or without Crohn's disease or ulcerative colitis are eligible to join. If you agree to join the study, the investigators will ask for information about your health. The investigators will also ask you to give us a blood sample so that they may discover the genes that cause IBD. The blood sample may be collected at Johns Hop... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
10/17/2024
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland
Conditions: Inflammatory Bowel Disease
Register for Updates
Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease
NCT05119556
Recruiting
The purpose of this study is to compare the efficacy and safety of a real time video telehealth pulmonary rehabilitation intervention with standard of care in patients hospitalized for an exacerbation of chronic obstructive pulmonary disease (COPD) to determine the impact on hospital readmissions and respiratory morbidity, and to investigate the cost-effectiveness of the intervention.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
10/17/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
Evaluation of MN-166 (ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with ALS
NCT04057898
Recruiting
A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/17/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Continuous Treatment With PREVENA Therapy for 14 Days
NCT05614869
Recruiting
The purpose of this study is to demonstrate substantial equivalence in terms of safety to support an indication change related to the usage of Prevena Therapy for up to 14 days. The enrolled subject will undergo 1 of 4 surgery types and be evaluated for up to 90 days.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
10/14/2024
Locations: Sinai Hospital of Baltimore, Baltimore, Maryland
Conditions: Abdominal Surgery, Orthopedic Surgery, Cardiovascular Surgery, Vascular Surgery
Register for Updates
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
NCT05566769
Recruiting
NMOSDCopilot is a digital tool developed for the self-assessment of Neuromyelitis Optica Spectrum Disorder symptoms that impact patients' functioning and quality of life. It has been co-designed with the help of patient advocacy groups, NMOSD patients and medical experts. It includes a smartphone-based application for patients, connected to a web portal developed for healthcare professionals (HCSPs). The patient application is composed of vision, walking, cognition, and dexterity e-active tests... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2024
Locations: Johns Hopkins Outpatient Center (now called Levi Watkins, Jr., M.D., Outpatient Center), Baltimore, Maryland
Conditions: Neuromyelitis Optica
Register for Updates
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636
Recruiting
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies ha... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
10/14/2024
Locations: Greater Baltimore Medical Ctr, Baltimore, Maryland +1 locations
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Register for Updates
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
NCT03942653
Recruiting
A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2024
Locations: Univeristy of Maryland, Baltimore, Maryland
Conditions: Salivary Gland Carcinoma
Register for Updates
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
NCT05824728
Recruiting
This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks. Participants will receive both AGB101 and a placebo to take once a day for 6 weeks, with a 4-week washout in between. Participation will also involve physical/neurological exams, questionnaires, paper and pencil tests, providing blood and u... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
10/10/2024
Locations: Johns Hopkins, Baltimore, Maryland
Conditions: Parkinson Disease Psychosis
Register for Updates
Impact of NMES and HPRO on Recovery After SAH- Pilot Study
NCT03201094
Recruiting
The study purpose is to investigate the hypothesis that in adults with SAH, early neuromuscular electrical stimulation (NMES) and high protein supplementation (HPRO) will improve muscle mass, metabolic and inflammatory biomarker profiles, compared to SAH controls receiving standard of care interventions for nutrition and mobilization. The investigators will accomplish this by studying the effects of a high protein (HPRO) nutritional treatment as well as NMES intervention have upon muscle wasting... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2024
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Subarachnoid Hemorrhage, Muscle Atrophy, Inflammation, Nutritional and Metabolic Disease
Register for Updates
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
NCT04039464
Recruiting
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.
Gender:
ALL
Ages:
Between 3 months and 18 years
Trial Updated:
10/09/2024
Locations: Johns Hopkins Medical Institutions, Baltimore, Maryland
Conditions: Pediatric Pulmonary Hypertension
Register for Updates
Optimal Pacing Rate for Cardiac Resynchronization Therapy
NCT06445439
Recruiting
This is a prospective, randomized crossover study. The objective of the study is to determine if a pacing rate of 80 beats per minute (bpm) improves exercise tolerance during the 6-minute walk test. The investigators will randomly assign half of the participants to a starting rate of 60 bpm and then switch them to a rate of 80 bpm for 3 months, and vice versa.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
10/09/2024
Locations: MedStar Union Memorial Hospital, Baltimore, Maryland
Conditions: Atrial Fibrillation, Persistent
Register for Updates
Exercise and Nutrition Interventions During Chemotherapy K07
NCT03858153
Recruiting
Chemotherapy-induced peripheral neuropathy (CIPN) is a highly prevalent and severe side-effect of taxane chemotherapy, often used to treat breast cancer. Unfortunately there are very limited treatments for CIPN. This is a phase II randomized controlled trial to test the preliminary efficacy of exercise vs. nutrition education on CIPN, to systematically investigate the potential roles of inflammation and interoception, and to obtain data with a more accurate effect size to inform a future study.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: University of Maryland, Baltimore, Maryland
Conditions: Neuropathy;Peripheral
Register for Updates